The US FDA Approves Boehringer Ingelheim’s Jardiance and Synjardy for the Treatment of Type 2 Diabetes
Shots:
- The US FDA has approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children aged ≥10yrs. with T2D
- The P-III trial evaluating empagliflozin vs PBO in 157 patients aged 10-17yrs. with inadequately controlled T2D. The results showed that patients treated with empagliflozin were superior in reducing hemoglobin A1c @26wks.
- 52 patients had an average 0.2% decrease in hemoglobin A1c over 0.7% increase in hemoglobin A1c in the 53 patients taking PBO, reductions in fasting plasma glucose after not eating or drinking for 8hrs. Jardiance & Synjardy was approved in the US in 2014 & 2015, respectively.
Ref: PR Newswire | Image: Boehringer Ingelheim
Related News:- Eli Lilly Reports the US FDA’s Acceptance of sNDA for Jardiance to Treat Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
